Year 2007 Vol. 15 No 3

ORIGINAL INVESTIGATIONS

SPIRIDONOV S.V., ZHARKOV V.V., KURCHIN V.P.

REMOTE RESULTS OF POST-OPERATIVE RADIATION THERAPY IN PATIENTS WITH NON SMALL-CELLED LUNG CANCER WITH METASTASIS IN MEDIASTINAL LYMPH NODES

Unsatisfactory statistics of 3 and 5-year survival in the stage III of non small-celled lung cancer with mediastinal lymph nodes lesion requires searching new approaches for extension of patients’ life and clinical recovery. The aim of this study is the comparison of adjuvant radiation therapy effectiveness in total focal dose of 40 and 50GR for patients with non small-celled lung cancer with metastases in mediastinal lymph nodes, who underwent radical surgery operations. On application of adjuvant radiation therapy in total focal dose of 50 GR throughout the three-year period of observation, the survival rate is higher than in case of postoperative radiation therapy application in total focal dose of 40 GR, the difference was statistically reliable. The leading cause of patients’ death is distant metastases. High frequency of metastases in the bone should be noted. Taking into account this fact as well as the increasing evidence of adjuvant chemotherapy effectiveness, the question of systemic impact on the tumor after radical surgical treatment should be more pointed.

Keywords: non small-celled lung cancer, adjuvant radiation therapy.
p. 16 - 26 of the original issue
References
  1. Давыдов, М. И. Современные принципы выбора лечебной тактики и возможности хирургического лечения немелкоклеточного рака легкого / М. И. Давыдов, С. М. Волков, Б. Е. Полоцкий [Электронный ресурс]. – Минск, 2005. – Режим доступа: http://www.rosoncoweb.ru/library/8th_conf/. – Дата доступа: 23 05 06.
  2. Факторы прогноза при радикальном лечении больных немелкоклеточным раком легкого с метастазами в регионарных лимфоузлах / В. В. Жарков [и др.] // Актуальные проблемы онкологии и медицинской радиологии / НИИ онкологии и мед. радиологии им. Н.Н. Александрова. – Минск, 2002. – С. 188–202.
  3. Phase III comparison of concurrent chemotherapy plus radiotherapy (CR/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09) / K. S. Albain [et al.] // Proc. Am. Soc. Clin. Oncol. – 2003. – N 22. – P. 621. – Abstr. 2497.
  4. Le Chevalier, T. for the IALT Investigators. Results of the randomized international adjuvant lung cancer trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC) / T. Le Chevalier // Proc. Am. Soc. Clin. Oncol. – 2003. – N 22. – P. 3.
  5. Phase III study of amifostine in patients with locally advanced non-small cell lung cancer (NSCLC) receiving chemotherapy & hyperfractionated radiation (chemo/HFxRT): Radiation Therapy Oncology Group (RTOG) 98-01 / B. Movsas [et al.] // Proc. Am. Soc. Clin. Oncol. – 2003. – N 22. – P. 636. – Abstr. 2559.
  6. Mountain, C. F. Regional lymph node classification for staging lung cancer / C. F. Mountain, C. M. Dresler // Chest. – 1997. – Vol. 111. – P. 1718–1723.
  7. PORT meta-analysis trialists group: postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials // Lancet. – 1998. – Vol. 352. – P. 257-263.
  8. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small cell lung cancer / G. Scagliotti [et al.] // J. Natl. Cancer Inst. – 2003.– 95.– P. 1453-1461.
Contacts | ©Vitebsk State Medical University, 2007-2023